In addition to the primary outcome of SELECT, nominally statistically significant risk reductions were also seen in secondary efficacy endpoints, including heart failure composite endpoint, all-cause mortality, coronary revascularizations, sustained weight loss for 104 weeks, a 5-point nephropathy composite endpoint, and patients developing biochemical diabetes (at least one post-randomization glycated hemoglobin [HbA 1c ] 6.5%) [21]
Scientists figured out that we can write our own versions of these messages in a lab and inject them to trigger responses
These expenses increase medication costs slightly but the peace of mind is worth it
Translation into broad tobacco-control practice will definitely hinge on durability of abstinence effects, tolerability, cost, and access, so policy should prioritize targeted implementation and definitive pragmatic trials rather than immediate guideline expansion